Acrux completes Phase I trial of testosterone lotion
Wednesday, 06 October, 2004
Acrux (ASX: ACR) has completed a Phase I clinical trial of its testosterone metered-dose lotion for the treatment of hypogonadism, or low testosterone, in men.
The proof-of-concept study compared Acrux's product with the current market leader, a commercially available testosterone gel in five men with low testosterone. The trial was performed at Prince Henry's Institute of Medical Research in Melbourne, and was sponsored by Acrux subsidiary Acrux DDS.
The company will now seek advice on the appropriate regulatory path for approval in major world markets including the US, CEO Igor Gonda said.
3D-printed films provide targeted liver cancer treatment
Researchers have created drug-loaded, 3D-printed films that kill more than 80% of liver cancer...
Using your brain at work may ward off cognitive impairment
The harder your brain works at your job, the less likely you may be to have memory and thinking...
Repurposed drugs show promise in heart muscle regeneration
The FDA-approved medications, when given in combination, target two proteins that regulate the...
